Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$46.36
-2.61-5.33%
At close: -
$46.36
0.000.00%
After Hours: May 23, 4:00 PM EDT
Comments
Loading...
Akero Therapeutics Analyst Ratings and Price Targets | NASDAQ:AKRO | Benzinga
Akero Therapeutics Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Akero Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Citigroup
HC Wainwright & Co.
UBS
B of A Securities
Morgan Stanley
1calculated from analyst ratings
Analyst Ratings for Akero Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | — | Citigroup | Jonathan Woo60% | $80 → $78 | Maintains | Buy | Get Alert |
| 03/03/2025 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $72 → $75 | Maintains | Buy | Get Alert |
| 01/31/2025 | Buy Now | — | UBS | Eliana Merle43% | $42 → $109 | Maintains | Buy | Get Alert |
| 01/30/2025 | Buy Now | — | B of A Securities | Alexandria Hammond42% | $35 → $63 | Upgrade | Neutral → Buy | Get Alert |
| 01/28/2025 | Buy Now | — | Morgan Stanley | Michael Ulz64% | $46 → $96 | Maintains | Overweight | Get Alert |
| 01/28/2025 | Buy Now | — | Citigroup | Jonathan Woo60% | $65 → $80 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | — | Canaccord Genuity | Edward Nash66% | $56 → $73 | Maintains | Buy | Get Alert |
| 01/27/2025 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $72 | Maintains | Buy | Get Alert |
| 01/16/2025 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/18/2024 | Buy Now | — | Citigroup | Jonathan Woo60% | → $65 | Initiates | → Buy | Get Alert |
| 11/18/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 11/11/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/17/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 08/12/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | — | Reiterates | → Overweight | Get Alert |
| 06/12/2024 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | — | Reiterates | → Overweight | Get Alert |
| 06/11/2024 | Buy Now | — | Wolfe Research | Andy Chen41% | — | Initiates | → Outperform | Get Alert |
| 06/11/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | — | Evercore ISI Group | Liisa Bayko70% | $50 → $38 | Maintains | Outperform | Get Alert |
| 05/13/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 05/13/2024 | Buy Now | — | Canaccord Genuity | Edward Nash66% | $59 → $56 | Maintains | Buy | Get Alert |
| 04/22/2024 | Buy Now | — | B of A Securities | Alexandria Hammond42% | → $30 | Reinstates | → Neutral | Get Alert |
| 03/05/2024 | Buy Now | — | UBS | Eliana Merle43% | $39 → $42 | Maintains | Buy | Get Alert |
| 03/05/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $43 → $50 | Maintains | Buy | Get Alert |
| 03/01/2024 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $40 → $43 | Maintains | Buy | Get Alert |
| 11/14/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | → $40 | Reiterates | Buy → Buy | Get Alert |
| 10/12/2023 | Buy Now | — | UBS | Eliana Merle43% | $83 → $39 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | — | JP Morgan | Eric Joseph42% | $62 → $41 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $64 → $40 | Maintains | Buy | Get Alert |
| 10/11/2023 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | $69 → $39 | Maintains | Overweight | Get Alert |
| 10/11/2023 | Buy Now | — | Morgan Stanley | Michael Ulz64% | $70 → $33 | Maintains | Overweight | Get Alert |
| 10/04/2023 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | → $69 | Reiterates | Overweight → Overweight | Get Alert |
| 09/19/2023 | Buy Now | — | Cantor Fitzgerald | Prakhar Agrawal39% | → $69 | Initiates | → Overweight | Get Alert |
| 09/13/2023 | Buy Now | — | Evercore ISI Group | Liisa Bayko70% | $50 → $60 | Maintains | Outperform | Get Alert |
| 09/05/2023 | Buy Now | — | JP Morgan | Eric Joseph42% | $49 → $62 | Maintains | Overweight | Get Alert |
| 08/28/2023 | Buy Now | — | UBS | Eliana Merle43% | → $83 | Initiates | → Buy | Get Alert |
| 06/12/2023 | Buy Now | — | Morgan Stanley | Michael Ulz64% | $65 → $70 | Maintains | Overweight | Get Alert |
| 06/07/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $62 → $64 | Maintains | Buy | Get Alert |
| 05/17/2023 | Buy Now | — | Canaccord Genuity | Edward Nash66% | $58 → $59 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $64 → $62 | Maintains | Buy | Get Alert |
| 03/21/2023 | Buy Now | — | Canaccord Genuity | Edward Nash66% | $50 → $58 | Maintains | Buy | Get Alert |
| 03/20/2023 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | → $64 | Reiterates | → Buy | Get Alert |
| 01/27/2023 | Buy Now | — | Morgan Stanley | Michael Ulz64% | → $65 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 11/07/2022 | Buy Now | — | Morgan Stanley | Matthew Harrison61% | $30 → $40 | Maintains | Equal-Weight | Get Alert |
| 11/07/2022 | Buy Now | — | HC Wainwright & Co. | Ed Arce59% | $62 → $64 | Maintains | Buy | Get Alert |
| 09/14/2022 | Buy Now | — | Morgan Stanley | Matthew Harrison61% | $26 → $30 | Maintains | Equal-Weight | Get Alert |
| 09/14/2022 | Buy Now | — | Evercore ISI Group | Liisa Bayko70% | $10 → $50 | Upgrade | In-Line → Outperform | Get Alert |
FAQ
What is the target price for Akero Therapeutics (AKRO) stock?
The latest price target for Akero Therapeutics (NASDAQ:AKRO) was reported by Citigroup on May 13, 2025. The analyst firm set a price target for $78.00 expecting AKRO to rise to within 12 months (a possible 68.25% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
The latest analyst rating for Akero Therapeutics (NASDAQ:AKRO) was provided by Citigroup, and Akero Therapeutics maintained their buy rating.
When was the last upgrade for Akero Therapeutics (AKRO)?
The last upgrade for Akero Therapeutics Inc happened on January 30, 2025 when B of A Securities raised their price target to $63. B of A Securities previously had a neutral for Akero Therapeutics Inc.
When was the last downgrade for Akero Therapeutics (AKRO)?
There is no last downgrade for Akero Therapeutics.
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a maintained with a price target of $80.00 to $78.00. The current price Akero Therapeutics (AKRO) is trading at is $46.36, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
